Prostatitis is a relatively common urological disease that occurs in adult men. The U.S. National Institutes of Health (NIH) Advisory Committees divided prostatitis into four categories.[2,3] Of these, the incidence of category III disease, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is believed to be very high. Category III prostatitis is subdivided into the inflammatory type (IIIA; similar to nonbacterial CP) and non-inflammatory type (IIIB; similar to prostatodynia) based on the presence (IIIA) or absence (IIIB) of leukocytes in prostatic secretions or seminal plasma.[2,3]
While the cause of CP/CPPS is presently unknown, it is a disease that has many clinical issues because it is often resistant to various treatments.[4–6] To date, CP/CPPS has been treated using alpha-blockers, antibacterial agents, anti-inflammatory agents, and phytotherapeutic agents with varying outcomes.[4–12] Phytotherapeutic agents that have been used include pollen extract, quercetin, and saw palmetto. Several years ago, Wagenlehner FM et al. announced the results of a prospective, randomized placebo-controlled study, which indicated that the pollen extract (Cernilton) significantly improved the total symptoms, pain, and quality of life in patients with inflammatory prostatitis/chronic pelvic pain syndrome (CP/CPPS) without any severe adverse effects.
Eviprostat is a phytotherapeutic agent widely used in the treatment of prostatic hypertrophy and has been used in Japan and Germany for more than 40 years.[13–15] Eviprostat consists of five components: four are extracted from the umbellate wintergreen Chimaphila umbellata, the aspen Populus tremula, the small pasque flower Pulsatilla pratensis, and the field horsetail Equisetum arvense, and the fifth is germ oil from wheat (Tritium aestivum).[13–15]
Oka et al. administered Eviprostat treatment in a rat model of nonbacterial prostatitis and reported that oxidative stress and proinflammatory cytokines in the enlarged prostate were considerably suppressed, and that Eviprostat may be useful in the clinical treatment of CP/CPPS.[13–15] Here we conducted a randomized prospective study to determine the effectiveness and safety of Eviprostat to treat CP/CPPS in comparison with pollen extract.
BMC Urol. 2015;15(120) © 2015 BioMed Central, Ltd.